Tranexamic acid
General properties
Antihemorrhagic drugs, antifibrinolytic amino acids. fibrinolysis inhibitors.
Medicinal product Tranexamic Acid is indicated in patients with haemophilia for short-term administration (within 2-8 days) to reduce or prevent bleeding and to reduce the need for replacement therapy during and after tooth extraction.
– Acquired color vision impairment (this eliminates the possibility of measuring one endpoint, which should be monitored as an indicator of toxicity).
– Subarachnoid hemorrhage (tranexamic acid may cause cerebral edema and cerebral infarction).
– Active intravascular coagulation.
– Hypersensitivity to tranexamic acid or to the excipient.
Pharmaceutical characteristics
Clear colorless to slightly brown liquid.
Store in the original packaging at temperature not exceeding 25 0C. Keep out of reach of children.
